Medivation and partner Astellas Pharma have announced positive results from the Phase III trial PREVAIL investigating Xtandi (enzalutamide) in patients with chemotherapy-naive metastatic prostate cancer (mPRC) which have failed androgen-deprivation therapy and have few or no symptoms. The randomised, double-blind, placebo-controlled, multi-national trial enrolled more than 1,700 patients across the United States, Canada, Europe, Australia, Russia, Israel, and Asian countries including Japan. The study met its co-primary endpoint as treatment with enzalutamide resulted in a significant improvement in overall survival compared to placebo, reducing the risk of death by 29% Other adverse events included hypertension (13.4% versus 4.1% in placebo) and Grade 3 cardiac events (2.8% versus 2.1% in placebo). The data will be presented at the American Society of Clinical Oncology (ASCO) meeting in San Francisco on 30 January 2014.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,655 JPY | -0.12% |
|
+2.83% | -1.84% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.84% | 18.82B | |
+63.11% | 856B | |
+38.95% | 631B | |
-4.23% | 359B | |
+17.63% | 325B | |
+8.69% | 297B | |
+6.05% | 234B | |
+16.57% | 226B | |
+15.38% | 177B | |
+1.95% | 165B |
- Stock Market
- Equities
- 4503 Stock
- News Astellas Pharma Inc.
- Astellas and Medivation Announce Positive Phase III for Xtandi in mPRC